GetTopicDetailResponse(id=28d0103355b8, topicName=默克PD-1單抗, introduction=默克PD-1單抗, content=null, image=null, comments=3, allHits=1132, url=https://h5.medsci.cn/topic?id=103355, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=97430, tagList=[TagDto(tagId=97430, tagName=默克PD-1單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2004580, encodeId=3b7e2004580ef, content=<a href='/topic/show?id=28d0103355b8' target=_blank style='color:#2F92EE;'>#默克PD-1單抗#</a>, objectTitle=默克PD-1單抗Keytruda：獲得FDA批準乳腺癌適應(yīng)癥, objectType=article, longId=203465, objectId=f0b620346555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b620346555, replyNumber=0, likeNumber=73, createdTime=2021-03-26, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b620346555, moduleTitle=默克PD-1單抗Keytruda：獲得FDA批準乳腺癌適應(yīng)癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f0b620346555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004579, encodeId=8bdf20045e959, content=<a href='/topic/show?id=28d0103355b8' target=_blank style='color:#2F92EE;'>#默克PD-1單抗#</a>, objectTitle=FDA批準默克PD-1單抗Keytruda的六周給藥方案--減少了疫情期間患者的看病頻率, objectType=article, longId=193319, objectId=6adc193319bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6adc193319bd, replyNumber=0, likeNumber=110, createdTime=2020-12-13, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6adc193319bd, moduleTitle=FDA批準默克PD-1單抗Keytruda的六周給藥方案--減少了疫情期間患者的看病頻率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6adc193319bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004578, encodeId=b70520045e8d8, content=<a href='/topic/show?id=28d0103355b8' target=_blank style='color:#2F92EE;'>#默克PD-1單抗#</a>, objectTitle=默克PD-1單抗KEYTRUDA（pembrolizumab）目前在美國獲批的所有適應(yīng)癥：14種癌癥的治療, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=79, createdTime=2020-01-06, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1單抗KEYTRUDA（pembrolizumab）目前在美國獲批的所有適應(yīng)癥：14種癌癥的治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
